Biocon founder Kiran Mazumdar Shaw says she is confident that the company’s investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg’s Haslinda Amin. (Source: Bloomberg)
Trending
- LARRY KUDLOW: Now is the time for Jay Powell to resign
- Canada fights stigma over standing liquidity facility
- Evernorth Wins Shareholder Vote for Nasdaq XRP Treasury Listing
- Finastra Launches AI Feature to Help Banks Resolve Payment Errors
- Stocks making the biggest moves midday: ACN SNPS UTHR VICR
- The hidden silver lining of high interest rates: safer, cheaper retirement income
- Sri Lanka holds rates as inflation remains high
- Crypto industry gave $8 million to Clarity Act lobbyists who didn’t close the deal
Friday, October 2
